Broadview Ventures

Relief Cardiovascular is a medical technology company focused on developing an innovative implantable device aimed at treating congestive heart failure. The company's smart implant is designed to monitor blood flow and alleviate congestion in the heart, which may lead to improved health outcomes for patients suffering from this condition. By providing a targeted treatment option, Relief Cardiovascular seeks to enhance the management of heart failure and improve the quality of life for affected individuals.

Alveron Pharma is focused on developing innovative treatments for hemorrhagic stroke and various thromboembolic disorders, addressing significant unmet medical needs. The company’s lead product, OKL-1111, is an injection solution designed to reduce hematoma expansion in cases of intracranial hemorrhage, moving away from complex pre-treatment processes. Additionally, Alveron is working on a cyclodextrin-based anticoagulant reversal drug, which aims to provide effective solutions for excessive bleeding related to conditions such as hemophilia, trauma, and surgical procedures. By advancing its coagulation technology, Alveron Pharma strives to enhance therapeutic options for medical practitioners dealing with acute and long-term bleeding complications.

Aria CV, Inc. is a medical device company based in St. Paul, Minnesota, founded in 2010 by Drs. John Scandurra and Karl Vollmers. The company specializes in developing an implantable cardiovascular device aimed at treating pulmonary arterial hypertension (PAH). This innovative device is designed to reduce the workload on the right side of the heart, potentially enhancing both survival rates and the quality of life for patients suffering from this condition. Aria CV holds an exclusive license for certain patents from the University of Minnesota, reflecting its strong ties to academic research and innovation in the field of medical devices.

CorFlow Therapeutics is a medtech startup focused on developing innovative technologies for the diagnosis and treatment of microvascular obstructions (MVO) in patients experiencing severe heart attacks. The company has created a controlled flow infusion system that measures the degree of MVO through a proprietary concept known as dynamic microvascular resistance. This system provides interventional cardiologists with critical data that can be compared to post-procedure contrast-enhanced magnetic resonance imaging. By enabling accurate diagnosis and treatment of MVO, CorFlow aims to reduce both short- and long-term complications in heart attack patients, addressing significant unmet medical needs in cardiovascular care.

XII Medical is a medical device developer focused on creating innovative solutions for obstructive sleep apnea. The company has developed a minimally invasive outpatient technology that includes an implantable neurostimulation device designed to alleviate the condition. This device works by preventing the muscles in the throat from relaxing during sleep, thereby avoiding airway blockage and enabling patients to enhance oropharyngeal airflow. Through its advancements in sleep apnea treatment, XII Medical aims to improve patient outcomes and provide a proactive approach to managing this common sleep disorder.

CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

IsomAb is a biotechnology company focused on the evaluation and development of isoform-specific antibodies aimed at treating diseases, particularly those related to peripheral arterial disease. The company utilizes a platform that targets specific isoforms of proteins altered in disease, particularly in the context of pathogenic messenger ribonucleic acid splicing and vascular endothelial growth factor A. By addressing both pro-angiogenic and anti-angiogenic isoforms, IsomAb's approach seeks to enhance blood flow and mitigate the effects of ischaemic diseases, offering potential treatment options for patients with limited alternatives.

Cardiosense develops a physiological waveform AI platform aimed at creating predictive biomarkers for the detection and treatment of cardiac diseases. The company utilizes raw biosignals and advanced signal processing techniques to gain insights into cardiac functions and identify pre-symptomatic markers of cardiac conditions. By leveraging multi-sensor devices and proprietary algorithms, Cardiosense focuses on non-invasive monitoring solutions that enhance healthcare professionals' ability to analyze cardiac health data and track patient well-being. This innovative approach facilitates early detection of diseases, ultimately aiming to improve patient outcomes in cardiac care.

Nyra Medical is focused on creating innovative transcatheter heart valve repair technology aimed at treating mitral regurgitation. The company's device is designed to address the leaflets of heart valves while preserving the natural geometry of the mitral valve. By utilizing a proprietary implant, Nyra Medical's technology enables patients to achieve consistent correction of valve regurgitation, improving their overall heart function.

RapidPulse, Inc. is a privately held medical device company focused on developing innovative minimally invasive vascular products for the treatment of ischemic stroke. The company's flagship product is the RapidPulse™ Cyclic Aspiration System, which features a novel aspiration pump designed to facilitate the rapid and consistent removal of blood clots from the brain. This technology aims to enhance patient outcomes in the neurovascular field. RapidPulse originated as a spinout from Syntheon LLC, a medical device incubator dedicated to fostering advancements in the industry.

XII Medical is a medical device developer focused on creating innovative solutions for obstructive sleep apnea. The company has developed a minimally invasive outpatient technology that includes an implantable neurostimulation device designed to alleviate the condition. This device works by preventing the muscles in the throat from relaxing during sleep, thereby avoiding airway blockage and enabling patients to enhance oropharyngeal airflow. Through its advancements in sleep apnea treatment, XII Medical aims to improve patient outcomes and provide a proactive approach to managing this common sleep disorder.

HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company's innovative approach involves targeting a heart-specific regulator of fibrosis, specifically a long noncoding RNA, to block myocardial fibrosis. This biopharmaceutical therapy aims to improve the efficacy and safety of treatment for heart-related illnesses and other serious health conditions associated with aging, including cancer. By concentrating on tissue and cell-selective genomic medicines, HAYA Therapeutics seeks to provide more precise and effective therapeutic options for patients suffering from these conditions.

CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

Puzzle Medical Devices Inc., founded in 2018 and based in Montreal, Canada, focuses on developing innovative heart pump technologies for treating advanced heart failure. The company's flagship product, the ModulHeart, is a modular percutaneous heart pump designed to reduce cardiac afterload and enhance renal perfusion in patients who are not candidates for heart transplant or surgical mechanical circulatory support. Its unique design allows for multiple pumps to be anchored in parallel within the descending aorta, facilitating hemodynamic support while minimizing risks associated with traditional procedures, such as bleeding and stroke. The ModulHeart aims to improve patient outcomes by providing sustained symptom relief, reducing hospital readmissions, and enhancing overall quality of life. Puzzle Medical has made significant progress, including completing its first-in-human study with positive results in cardiac and kidney function, receiving FDA Breakthrough Device Designation, and establishing a strong network of Key Opinion Leaders in the field.

Kantum Pharma, operating as Kantum Bio, focuses on developing therapeutic and diagnostic solutions for acute kidney injury (AKI). Established in 2016 and based in Concord, New Hampshire, the company is advancing its lead therapeutic candidate, KB-1801, aimed at preventing and treating AKI, particularly in patients undergoing cardiovascular interventions. This therapy also shows promise for conditions associated with AKI in intensive care settings, such as sepsis and nephrotoxicity. In conjunction with its therapeutic development, Kantum is creating a novel diagnostic test, utilizing Uridine diphosphate glucose (UDP-G), which will facilitate early diagnosis of patients at risk for AKI. This diagnostic tool is intended to assist clinicians in identifying at-risk patients and guiding their treatment in both clinical studies and practice, ultimately aiming to reduce the mortality associated with AKI.

RapidPulse, Inc. is a privately held medical device company focused on developing innovative minimally invasive vascular products for the treatment of ischemic stroke. The company's flagship product is the RapidPulse™ Cyclic Aspiration System, which features a novel aspiration pump designed to facilitate the rapid and consistent removal of blood clots from the brain. This technology aims to enhance patient outcomes in the neurovascular field. RapidPulse originated as a spinout from Syntheon LLC, a medical device incubator dedicated to fostering advancements in the industry.

Fineheart is a France-based medical device company that specializes in innovative technologies aimed at addressing cardiovascular diseases. The company is developing an implantable cardiac device that is wirelessly powered and fully implantable, designed to provide mechanical circulatory support. This novel device optimizes cardiac output while preserving the heart's natural contractility, thereby enabling patients with heart failure to restore normal cardiac function and improve their quality of life. Fineheart's focus on advanced medical solutions positions it as a key player in the evolving landscape of cardiovascular care.

HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company's innovative approach involves targeting a heart-specific regulator of fibrosis, specifically a long noncoding RNA, to block myocardial fibrosis. This biopharmaceutical therapy aims to improve the efficacy and safety of treatment for heart-related illnesses and other serious health conditions associated with aging, including cancer. By concentrating on tissue and cell-selective genomic medicines, HAYA Therapeutics seeks to provide more precise and effective therapeutic options for patients suffering from these conditions.

HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company's innovative approach involves targeting a heart-specific regulator of fibrosis, specifically a long noncoding RNA, to block myocardial fibrosis. This biopharmaceutical therapy aims to improve the efficacy and safety of treatment for heart-related illnesses and other serious health conditions associated with aging, including cancer. By concentrating on tissue and cell-selective genomic medicines, HAYA Therapeutics seeks to provide more precise and effective therapeutic options for patients suffering from these conditions.

Basking Biosciences is a startup focused on developing a reversible thrombolytic therapy aimed at restoring blood flow to the brain during ischemic strokes, thereby preventing hemorrhage and minimizing long-term damage. The company’s innovative approach involves a paired therapy that combines an active agent targeting a crucial component of clot stability with a designed reversal agent. This reversal agent can be administered if bleeding occurs, effectively neutralizing the active compound and restoring the blood's normal clotting ability. By enabling healthcare professionals to treat acute ischemic stroke effectively, Basking Biosciences aims to improve patient outcomes in critical medical situations.

Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company specializes in developing peptide drugs aimed at treating dietary-related metabolic diseases, including obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics focuses on creating peptide-based GIP receptor antagonists, which are designed to monitor and manage these metabolic conditions by reducing blood flow and lipid uptake in adipose tissue.

Alleviant Medical, Inc. is a medical device company focused on developing therapies for congestive heart failure. Founded in 2017 and headquartered in Austin, Texas, the company offers a proprietary transcatheter device designed to provide minimally invasive treatment for heart failure. This innovative technology aims to relieve pressure buildup in the left atrium, which can lead to organ failures, thereby alleviating symptoms of heart failure. By improving patients' quality of life and reducing hospital admissions due to heart failure exacerbations, Alleviant Medical addresses the needs of over 6 million Americans suffering from this condition.

AtaCor Medical, Inc. is a medical device company based in San Clemente, California, focused on cardiac pacing and rhythm management. Founded in 2014, the company has developed the AtaCor EV Temporary Pacing System, an innovative implantable system that utilizes a parasternal approach to provide temporary pacing without the need for traditional leads or hardware attached to the heart. This system introduces a pacing lead into the extracardiac tissue located between the ribs and pericardium, allowing for quick and effective restoration of cardiac rhythm in patients. AtaCor Medical aims to enhance the delivery of temporary, interim, and permanent cardiac pacing solutions in critical situations.

Puzzle Medical Devices Inc., founded in 2018 and based in Montreal, Canada, focuses on developing innovative heart pump technologies for treating advanced heart failure. The company's flagship product, the ModulHeart, is a modular percutaneous heart pump designed to reduce cardiac afterload and enhance renal perfusion in patients who are not candidates for heart transplant or surgical mechanical circulatory support. Its unique design allows for multiple pumps to be anchored in parallel within the descending aorta, facilitating hemodynamic support while minimizing risks associated with traditional procedures, such as bleeding and stroke. The ModulHeart aims to improve patient outcomes by providing sustained symptom relief, reducing hospital readmissions, and enhancing overall quality of life. Puzzle Medical has made significant progress, including completing its first-in-human study with positive results in cardiac and kidney function, receiving FDA Breakthrough Device Designation, and establishing a strong network of Key Opinion Leaders in the field.

HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company's innovative approach involves targeting a heart-specific regulator of fibrosis, specifically a long noncoding RNA, to block myocardial fibrosis. This biopharmaceutical therapy aims to improve the efficacy and safety of treatment for heart-related illnesses and other serious health conditions associated with aging, including cancer. By concentrating on tissue and cell-selective genomic medicines, HAYA Therapeutics seeks to provide more precise and effective therapeutic options for patients suffering from these conditions.

Kantum Pharma, operating as Kantum Bio, focuses on developing therapeutic and diagnostic solutions for acute kidney injury (AKI). Established in 2016 and based in Concord, New Hampshire, the company is advancing its lead therapeutic candidate, KB-1801, aimed at preventing and treating AKI, particularly in patients undergoing cardiovascular interventions. This therapy also shows promise for conditions associated with AKI in intensive care settings, such as sepsis and nephrotoxicity. In conjunction with its therapeutic development, Kantum is creating a novel diagnostic test, utilizing Uridine diphosphate glucose (UDP-G), which will facilitate early diagnosis of patients at risk for AKI. This diagnostic tool is intended to assist clinicians in identifying at-risk patients and guiding their treatment in both clinical studies and practice, ultimately aiming to reduce the mortality associated with AKI.

CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

Renovacor, Inc. is a preclinical-stage biopharmaceutical company based in Philadelphia, Pennsylvania, dedicated to developing gene therapies for cardiovascular diseases. Founded in 2013, the company focuses on innovative treatments for dilated cardiomyopathy (DCM), particularly cases caused by mutations in the BAG3 gene. This condition affects over 3 million individuals in the United States, with around 35,000 patients estimated to have BAG3 mutations, classifying it as an orphan disease. Patients with BAG3-associated DCM, often younger and experiencing faster disease progression, currently have limited treatment options, primarily consisting of standard heart failure care. Renovacor's lead program involves a recombinant adeno-associated virus (AAV)-based gene therapy aimed at replacing the defective BAG3 gene, which holds the potential to prevent disease progression and improve outcomes for this vulnerable patient population.

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company that specializes in developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. Utilizing its proprietary XTreo technology platform, the company aims to deliver medications directly to affected tissues for extended periods with a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy specifically for chronic rhinosinusitis. The active ingredient in these formulations is mometasone furoate, which is recognized for its efficacy and safety in various FDA-approved therapies. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics was formerly known as 480 Biomedical, Inc. before rebranding in July 2018.

AtaCor Medical, Inc. is a medical device company based in San Clemente, California, focused on cardiac pacing and rhythm management. Founded in 2014, the company has developed the AtaCor EV Temporary Pacing System, an innovative implantable system that utilizes a parasternal approach to provide temporary pacing without the need for traditional leads or hardware attached to the heart. This system introduces a pacing lead into the extracardiac tissue located between the ribs and pericardium, allowing for quick and effective restoration of cardiac rhythm in patients. AtaCor Medical aims to enhance the delivery of temporary, interim, and permanent cardiac pacing solutions in critical situations.

Vectorious Medical Technologies Ltd. is a medical device company based in Tel Aviv, Israel, established in 2011. The company specializes in developing and manufacturing advanced cardiac monitoring systems for patients with congestive heart failure. Its flagship product, the V-LAP, is the world's first in-heart microcomputer that provides daily, push-button readings of left atrial pressure (LAP), the earliest and most reliable indicator of heart failure deterioration. This innovative device is miniature, wireless, and battery-less, allowing it to communicate effectively from within the body. Vectorious is currently conducting clinical trials in several European countries, including Italy, Germany, and the UK, aiming to obtain a CE mark for its product. Additionally, plans for a clinical study in the United States were anticipated to commence in 2020. Through its technology, Vectorious aims to enhance the quality of life and life expectancy for individuals suffering from heart failure.

G.I. Windows, Inc. is a clinical-stage company based in West Bridgewater, Massachusetts, specializing in the manufacture of medical devices that utilize surgical anastomotic technology. Founded in 2012, the company aims to revolutionize surgical procedures by developing less invasive techniques for treating obesity and type 2 diabetes. G.I. Windows is focused on creating innovative solutions that not only enhance patient outcomes but also contribute to cost reduction in the healthcare system. Through its commitment to advancing surgical technology, the company seeks to establish a new category in healthcare, enabling the development of procedures that are novel and less invasive.

Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company specializes in developing peptide drugs aimed at treating dietary-related metabolic diseases, including obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics focuses on creating peptide-based GIP receptor antagonists, which are designed to monitor and manage these metabolic conditions by reducing blood flow and lipid uptake in adipose tissue.

Adient Medical Inc. is a company specializing in the development and delivery of implantable and absorbable medical devices, primarily focused on preventing pulmonary embolisms. Founded in 2012 and headquartered in Pearland, Texas, Adient Medical aims to create devices that are safe and effective throughout their intended use, and then naturally dissolve without the need for surgical removal. This innovative approach not only enhances patient safety but also reduces the potential for complications and the costs associated with removal procedures. Through its absorbable vascular filter, Adient Medical provides healthcare professionals with a safer alternative for managing the risk of pulmonary embolism in patients.

Mellitus, LLC is a biotechnology company based in Boston, Massachusetts, that specializes in developing in vitro diagnostic tests for diabetes management. The company focuses on its novel test for measuring Glycated CD59 (GCD59), a biomarker with potential applications in the screening, diagnosis, and monitoring of diabetes. This test is particularly aimed at identifying gestational diabetes mellitus and assessing the risk of complications associated with the condition. Additionally, Mellitus's technology serves as a clinical trial tool for pharmaceutical development, enabling healthcare professionals to evaluate diabetes-related risks effectively. Founded in 2011, the company is dedicated to advancing diagnostic solutions in the field of diabetes care.

CellAegis Devices Inc. is a Toronto-based company that develops, manufactures, and commercializes medical devices aimed at enhancing cardiovascular care. Its flagship product, the autoRIC Device, delivers remote ischemic conditioning (RIC) in a non-invasive manner, providing critical therapy to minimize heart damage during heart attacks and various cardiovascular procedures. Additionally, the company offers CRICtrac, a mobile application that enables clinicians to administer self-delivered chronic RIC therapy to patients at home. CellAegis Devices caters to a wide range of settings, including hospitals, ambulances, and home care, and serves markets in Canada, Europe, and the United States.

Nido is a medical device manufacturer focused on developing innovative solutions for cardiac care. The company is working on SEPIA, an advanced Epicardial Ablation Solution designed to address cardiac arrhythmias, specifically ventricular tachycardia. This novel platform allows for video-endoscopic trans-cardiac surgical repairs within the beating heart, facilitating minimally invasive procedures. By utilizing small incisions in the chest and heart wall, Nido's technology enables physicians to perform intricate intracardiac surgeries without the need for cardiopulmonary bypass, representing a significant advancement in the field of cardiac surgery.

Aeromics, LLC is a preclinical company based in Cleveland, Ohio, focused on developing treatments for cerebral edema, particularly in stroke patients. It specializes in AER-271, a drug candidate that inhibits aquaporin-4 (AQP4), a key molecular water channel at the blood-brain barrier responsible for regulating fluid balance in the brain. This innovative therapy aims to address conditions such as ischemic stroke, cardiac arrest, and water toxicity by effectively reducing edema. Founded in 2006, Aeromics operates as a subsidiary of Case Western Reserve University, leveraging a paradigm shift in understanding water physiology and the role of aquaporins in various diseases. The company's research has the potential to provide a significant advancement in acute intravenous therapies for cerebral edema, thereby improving recovery outcomes for affected patients.

Fineheart is a France-based medical device company that specializes in innovative technologies aimed at addressing cardiovascular diseases. The company is developing an implantable cardiac device that is wirelessly powered and fully implantable, designed to provide mechanical circulatory support. This novel device optimizes cardiac output while preserving the heart's natural contractility, thereby enabling patients with heart failure to restore normal cardiac function and improve their quality of life. Fineheart's focus on advanced medical solutions positions it as a key player in the evolving landscape of cardiovascular care.

Gila Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Minneapolis, Minnesota, focused on developing therapies for obesity. Established in 2014, the company is working on GT-002, a PYY3-36 agonist designed to reduce caloric intake and promote weight loss. Gila Therapeutics employs innovative routes of administration to create non-invasive treatments for metabolic diseases, aiming to increase feelings of fullness and help individuals manage their weight effectively.

Aria CV, Inc. is a medical device company based in St. Paul, Minnesota, founded in 2010 by Drs. John Scandurra and Karl Vollmers. The company specializes in developing an implantable cardiovascular device aimed at treating pulmonary arterial hypertension (PAH). This innovative device is designed to reduce the workload on the right side of the heart, potentially enhancing both survival rates and the quality of life for patients suffering from this condition. Aria CV holds an exclusive license for certain patents from the University of Minnesota, reflecting its strong ties to academic research and innovation in the field of medical devices.

480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown, Massachusetts.

Epirium Bio, Inc. is a San Diego-based biopharmaceutical company focused on developing therapeutic compounds for cardiovascular diseases, metabolic syndrome, and various conditions related to mitochondrial dysfunction. Founded in 2008 and previously known as Cardero Therapeutics, Epirium Bio utilizes innovative insights into mitochondrial biology and tissue regeneration to create small molecule therapies. The company's research is aimed at enhancing muscle strength and supporting the treatment of neuromuscular and neurodegenerative disorders, including conditions such as muscular dystrophy. Through its novel approaches, Epirium Bio seeks to provide clinically significant solutions for patients suffering from these challenging diseases.

Pulmokine is a privately held biopharmaceutical company dedicated to developing therapies for challenging pulmonary diseases, specifically focusing on conditions such as pulmonary arterial hypertension (PAH), pulmonary arterial fibrosis, interstitial lung disease, sarcoidosis, and lung cancer. Leveraging innovative kinase inhibitor technology, Pulmokine aims to create effective treatments that address the needs of patients suffering from these serious lung conditions. Through its targeted approach, the company seeks to improve patient outcomes and expand the options available for managing difficult-to-treat pulmonary ailments.

Viridian Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative treatments for patients with diseases that lack effective therapies. The company focuses on addressing conditions such as thyroid eye disease, a debilitating orphan disease characterized by inflammation and swelling of the eye muscles. One of its key product candidates, VRDN-001, is an insulin-like growth factor-1 receptor monoclonal antibody designed to potentially treat this condition. Viridian Therapeutics aims to provide new options for patients suffering from these underserved medical needs through its advanced research and development initiatives.

Acesion Pharma ApS is a biotech company based in Copenhagen, Denmark, founded in 2011. The company specializes in the development of medical drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. Acesion Pharma focuses on creating SK channel inhibitors, which target specific ion channels in heart cells that are essential for generating the electrical signals that regulate heart rhythm. By inhibiting these channels, the company aims to provide safe and tolerable chronic treatments that prevent the recurrence of AF and support the maintenance of a normal heart rhythm.

Ischemia Care, LLC is a molecular diagnostic company based in Oxford, Ohio, specializing in blood tests designed to aid physicians in diagnosing the causes of ischemic strokes and transient ischemic attacks. The company offers a range of diagnostic services, including ISCDx, a test that employs gene expression analysis to identify stroke causes, and various laboratory tests performed in hospital settings. Its products, such as the ER Stroke Triage Test, support emergency room clinicians in confirming strokes quickly. By utilizing blood testing as a clinical workflow tool, Ischemia Care aims to improve patient outcomes and reduce healthcare costs by ensuring patients receive appropriate treatment pathways to prevent recurrence. Established in 2002, the company was formerly known as Gerard Ventures, LLC, before rebranding in 2011.

Viridian Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative treatments for patients with diseases that lack effective therapies. The company focuses on addressing conditions such as thyroid eye disease, a debilitating orphan disease characterized by inflammation and swelling of the eye muscles. One of its key product candidates, VRDN-001, is an insulin-like growth factor-1 receptor monoclonal antibody designed to potentially treat this condition. Viridian Therapeutics aims to provide new options for patients suffering from these underserved medical needs through its advanced research and development initiatives.

InfoBionic, Inc., founded in 2011 and based in Lowell, Massachusetts, specializes in remote patient monitoring and cardiac diagnostic services through its cloud-based platform, MoMe™. The MoMe System is designed to enhance the detection of cardiac arrhythmias, allowing healthcare providers to access vital patient data anytime and anywhere. By replicating in-hospital telemetry data, the platform streams continuous electrocardiogram, respiration, and motion data to the cloud for real-time analysis. This innovation aims to improve clinical efficiency and patient care, enabling physicians to monitor and treat cardiac complications effectively.

ZZ Biotech, LLC, founded in 2006 and based in Houston, Texas, is a clinical-stage company focused on developing biological treatments for ischemic stroke and neurodegenerative disorders. The company is advancing 3K3A-APC, a genetically engineered variant of the naturally occurring activated protein C (APC). Unlike its predecessor, 3K3A-APC significantly reduces the risk of bleeding while maintaining beneficial cell-protective and anti-inflammatory properties. Preclinical studies have demonstrated that 3K3A-APC offers enhanced efficacy compared to wild-type APC, particularly when used in conjunction with tissue plasminogen activator (tPA). Currently, ZZ Biotech is conducting a multicenter Phase 2 clinical trial to assess the safety, tolerability, and effectiveness of 3K3A-APC in patients with acute ischemic stroke, supported by funding from the National Institutes of Health. Through its innovative approach, ZZ Biotech aims to improve treatment options for patients suffering from acute neurological conditions.

Remedy Pharmaceuticals, Inc. is a clinical stage pharmaceutical company based in New York, founded in 2004. The company is dedicated to developing small molecule drugs aimed at addressing acute central nervous system disorders, such as stroke, traumatic brain injury, spinal cord injury, and organ ischemia. Remedy Pharmaceuticals leverages its expertise in targeting NCCa-ATP channels to create innovative therapies, including RP-1127, an intravenous formulation of glyburide, which acts as an inhibitor of these channels. By focusing on these critical areas, the company aims to provide effective treatment options for patients suffering from severe nervous system-related conditions.

Apama Medical, Inc. is a medical device company based in Campbell, California, specializing in catheter ablation technology for the treatment of atrial fibrillation (AF). Established in 2009, the company has developed an innovative radiofrequency (RF) balloon catheter system that integrates multiple electrodes and combines the advantages of both RF point-by-point and balloon-based ablation techniques. This system features built-in digital cameras, LED lights, and sensing electrodes, allowing for real-time visualization and assessment of catheter electrode contact during procedures. Apama Medical aims to enhance the detection and treatment of heart rhythm disorders, ultimately enabling shorter procedure times and improved patient outcomes. As of October 2017, Apama Medical operates as a subsidiary of Boston Scientific Corporation.

BioKier, Inc. is an early-stage pharmaceutical company headquartered in Chapel Hill, North Carolina. Established in 2008, the company focuses on developing treatments for diabetes and related disorders, including metabolic syndrome and obesity. BioKier specializes in proprietary oral medications designed to help individuals manage their glucose levels, mimicking the mechanism of metabolic bypass surgery. One of its key products is based on L-glutamine, a natural compound found in food, which serves as the active ingredient in its lead formulation for the treatment of type 2 diabetes.

Zumbro Discovery, Inc. is focused on developing a novel natriuretic peptide called MANP, aimed at addressing the treatment of resistant hypertension, a condition linked to significant health risks such as heart failure, myocardial infarction, stroke, and kidney disease. Discovered at the Mayo Clinic, MANP is poised to enter first-in-human studies, highlighting its potential to meet an urgent medical need. The innovative approach of Zumbro Discovery seeks to provide a rapid treatment option for hospitals, thereby improving the likelihood of successful patient outcomes in managing this challenging cardiovascular and metabolic condition.

DecImmune Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing innovative peptides and monoclonal antibodies aimed at addressing acute tissue-damaging inflammation. The company's therapeutics target conditions such as myocardial infarction, second-degree burns, vascular injury, and reperfusion injury in transplant patients. By focusing on an innate IgM-mediated autoimmune pathway, DecImmune Therapeutics seeks to enhance treatment options for various inflammatory diseases, including diabetic nephropathy and renal ischemia. Founded in 2001 and originally known as Natural Antibodies, Inc., the company rebranded in 2004 to reflect its commitment to advancing therapeutic solutions in the field of inflammation and autoimmunity.

Laurantis Pharma Oy is a specialty pharmaceutical development company with a broad, clinical-stage portfolio in three therapeutic areas: dermatology, ophthalmology, and oncology. Using two proprietary technologies, Laurantis is developing first-in-class products for commercially and medically significant niche indications in these areas. Laurantis was formed in December 2010 through a merger of the Finnish drug development companies Oy Lx Therapies Ltd and BioCis Pharma Oy.

Herantis Pharma is a biotechnology company focused on addressing unmet clinical needs through the development of disease-modifying therapies for Parkinson's disease. The company's primary development program centers on HER-096, a peptidomimetic molecule engineered to preserve the biological activity of the neuroprotective CDNF protein. By targeting the underlying mechanisms of the disease, Herantis Pharma aims to provide innovative treatment options for patients suffering from Parkinson's disease.

InfoBionic, Inc., founded in 2011 and based in Lowell, Massachusetts, specializes in remote patient monitoring and cardiac diagnostic services through its cloud-based platform, MoMe™. The MoMe System is designed to enhance the detection of cardiac arrhythmias, allowing healthcare providers to access vital patient data anytime and anywhere. By replicating in-hospital telemetry data, the platform streams continuous electrocardiogram, respiration, and motion data to the cloud for real-time analysis. This innovation aims to improve clinical efficiency and patient care, enabling physicians to monitor and treat cardiac complications effectively.

Viridian Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative treatments for patients with diseases that lack effective therapies. The company focuses on addressing conditions such as thyroid eye disease, a debilitating orphan disease characterized by inflammation and swelling of the eye muscles. One of its key product candidates, VRDN-001, is an insulin-like growth factor-1 receptor monoclonal antibody designed to potentially treat this condition. Viridian Therapeutics aims to provide new options for patients suffering from these underserved medical needs through its advanced research and development initiatives.

Vascular Graft Solutions Ltd. is an innovative company based in Israel, founded in 2009, that focuses on improving outcomes in bypass surgeries and enhancing patients' quality of life. The company specializes in developing external stents and scaffolds designed for cardiac and vascular surgery, specifically targeting the issues associated with vein graft diseases. Its leading product, VEST, is engineered for use in Coronary Artery Bypass Grafting (CABG) to reduce the failure rate of vascular grafts and address disease progression in venous bypass grafts, thereby improving their long-term performance. Vascular Graft Solutions aims to tackle complex challenges in surgical revascularization, vascular reconstruction, and arteriovenous fistula procedures.

CardiaLen, Inc. is a medical device company based in Minneapolis, Minnesota, specializing in the development of innovative therapies for atrial fibrillation and other heart arrhythmias. Founded in 2008, the company is focused on creating implantable, low-energy cardioverter devices that offer pain-free cardioversion therapies. These devices monitor the heartbeat and employ a proprietary series of low-energy pulses to restore normal heart rhythm while minimizing discomfort and preventing damage to heart tissue. By addressing significant unmet needs in the treatment of atrial fibrillation, CardiaLen aims to enhance patient outcomes and reduce reliance on high-energy defibrillation shocks.

Apama Medical, Inc. is a medical device company based in Campbell, California, specializing in catheter ablation technology for the treatment of atrial fibrillation (AF). Established in 2009, the company has developed an innovative radiofrequency (RF) balloon catheter system that integrates multiple electrodes and combines the advantages of both RF point-by-point and balloon-based ablation techniques. This system features built-in digital cameras, LED lights, and sensing electrodes, allowing for real-time visualization and assessment of catheter electrode contact during procedures. Apama Medical aims to enhance the detection and treatment of heart rhythm disorders, ultimately enabling shorter procedure times and improved patient outcomes. As of October 2017, Apama Medical operates as a subsidiary of Boston Scientific Corporation.

Provasculon is a biotechnology company focused on developing novel therapeutic proteins aimed at healing organs damaged by ischemia. Founded based on the discoveries of Richard Lee, MD, and Vincent Segers, MD, both affiliated with Brigham and Women's Hospital, Provasculon specializes in innovative applications of Stromal Cell-Derived Factor-1 (SDF-1). The company's lead therapeutic protein shows promise in restoring the function of hearts severely affected by ischemic conditions, potentially bringing them back to near normal performance. Through its research and development efforts, Provasculon seeks to address critical medical needs in the treatment of ischemic organ damage.

Aggamin Pharmaceuticals, LLC is a biotechnology company established in 2010 and located in New York. The company focuses on developing and commercializing innovative therapies for vascular diseases, with a primary emphasis on preeclampsia, a serious condition affecting about 5% of pregnancies and imposing a significant financial burden on the U.S. healthcare system. Aggamin's lead product is an extracorporeal device designed to reduce harmful circulating proteins associated with preeclampsia, aiming to improve both maternal and fetal health. By restoring the angiogenic balance disrupted in this condition, the company's objective is to provide a safe, first-in-class treatment that alleviates maternal symptoms, extends pregnancy duration, and enhances outcomes for both mothers and newborns.

Coridea is an idea generator, technology incubator, and consulting firm focused on the development of medical devices in the cardio-renal and cardio-pulmonary fields. Established in 2003, the company has successfully launched six startups, including notable firms like Ardian and CHF Solutions. The acquisition of Ardian by Medtronic, valued at $800 million, stands as a significant milestone in the medical device sector. Coridea has secured 65 U.S. patents, which have been licensed to various companies, and has raised over $150 million in venture capital financing. The company is recognized for its innovation, exemplified by the award-winning Symplicity® Catheter System™, which garnered the Edison Award in 2011. Coridea aims to provide physiologically-based solutions for complex medical challenges, impacting the lives of patients with cardiac, pulmonary, renal, and neuro conditions.

NuPulseCV, Inc. is a medical device company focused on developing innovative technologies for treating patients with heart failure. The company's primary product, the iVAS intravascular ventricular assist system, is an investigational device designed for advanced heart failure patients who do not benefit from standard medical therapies. This minimally invasive device allows for outpatient treatment, enabling patients to be discharged from the hospital. The iVAS system is currently undergoing clinical trials to evaluate its effectiveness in alleviating symptoms associated with advanced heart failure, particularly in patients classified as NYHA III and IV. Founded in 2010 and based in Raleigh, North Carolina, NuPulseCV benefits from the expertise of its founders in clinical, engineering, and life sciences, and maintains strategic partnerships to enhance its impact in the heart failure treatment landscape.

CardiaLen, Inc. is a medical device company based in Minneapolis, Minnesota, specializing in the development of innovative therapies for atrial fibrillation and other heart arrhythmias. Founded in 2008, the company is focused on creating implantable, low-energy cardioverter devices that offer pain-free cardioversion therapies. These devices monitor the heartbeat and employ a proprietary series of low-energy pulses to restore normal heart rhythm while minimizing discomfort and preventing damage to heart tissue. By addressing significant unmet needs in the treatment of atrial fibrillation, CardiaLen aims to enhance patient outcomes and reduce reliance on high-energy defibrillation shocks.

Capricor Therapeutics is a clinical-stage biotechnology company headquartered in Beverly Hills, California, specializing in the discovery, development, and commercialization of biological therapies for the treatment of diseases, particularly Duchenne muscular dystrophy (DMD) and other rare disorders. The company's lead product candidate, CAP-1002, is an allogeneic cell therapy currently in phase II clinical trials aimed at treating late-stage DMD. Additionally, Capricor has explored CAP-1002 for other cardiac conditions, including heart failure and post-myocardial infarction complications. The company is also developing CAP-2003, which is in pre-clinical development for inflammatory conditions, alongside other innovative therapeutic approaches, including exosome-based treatments and vaccines. Founded in 2005, Capricor Therapeutics is committed to addressing unmet medical needs through its advanced therapeutic programs.

CellAegis Devices Inc. is a Toronto-based company that develops, manufactures, and commercializes medical devices aimed at enhancing cardiovascular care. Its flagship product, the autoRIC Device, delivers remote ischemic conditioning (RIC) in a non-invasive manner, providing critical therapy to minimize heart damage during heart attacks and various cardiovascular procedures. Additionally, the company offers CRICtrac, a mobile application that enables clinicians to administer self-delivered chronic RIC therapy to patients at home. CellAegis Devices caters to a wide range of settings, including hospitals, ambulances, and home care, and serves markets in Canada, Europe, and the United States.

Intravascular Imaging focuses on developing advanced techniques for detecting and assessing atherosclerotic plaques in human arteries. Established through a collaboration between Massachusetts General Hospital/Harvard Medical School and the Technical University of Munich, the company aims to enhance cardiovascular imaging technologies. Its offerings include prototype devices, software, and systems designed to improve early detection of coronary artery disease and evaluate therapeutic viability after interventions. By providing a comprehensive catheter-based approach, Intravascular Imaging enables healthcare providers to identify high-risk plaques more effectively, thereby reducing hospital readmissions following percutaneous coronary interventions. This commitment to advancing biological imaging modalities underscores the company's dedication to improving patient outcomes in cardiovascular health.

Allosteros Therapeutics Inc. engages in discovery and development of breakthrough small molecule drugs that target allosteric sites on key proteins in disease pathways. Allosteros Therapeutics Inc. was incorporated in 2009 and is based in Palo Alto, California.

VentriNova is a regenerative medicine company dedicated to reversing cardiac damage through the activation of intrinsic repair pathways that generate new heart muscle cells. The company focuses on developing clinical treatments and gene therapies aimed at regenerating heart tissue. Its first-generation product is a gene therapy that delivers a critical mitotic regulator to diseased heart tissue, promoting the proliferation of cardiac muscle cells. This innovative approach enables healthcare providers to offer potential cures for patients suffering from heart failure.

Viridian Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative treatments for patients with diseases that lack effective therapies. The company focuses on addressing conditions such as thyroid eye disease, a debilitating orphan disease characterized by inflammation and swelling of the eye muscles. One of its key product candidates, VRDN-001, is an insulin-like growth factor-1 receptor monoclonal antibody designed to potentially treat this condition. Viridian Therapeutics aims to provide new options for patients suffering from these underserved medical needs through its advanced research and development initiatives.

CardiAQ Valve Technologies is a privately held company specializing in advanced solutions for heart valve replacement, with a primary focus on transcatheter mitral valve implantation (TMVI). The company has developed a system that allows physicians to implant a mitral valve within a beating heart, thereby eliminating the need for open-heart surgery. This innovative approach aims to enhance patient outcomes and simplify the procedure for both patients and healthcare providers.